Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $27.86M | $33.46M | $7.50M | $6.00M | $2.00M | N/A | $17.80M | N/A |
| Cost of Revenue | $7.93M | $2.00M | $975.00K | $680.00K | $60.00K | $989.00K | $1.03M | $1.59M |
| Gross Profit | $19.93M | $31.45M | $6.53M | $5.32M | $1.94M | $-989.00K | $16.77M | $-1.59M |
| Gross Margin | 71.54% | 94.01% | 87.00% | 88.67% | 97.00% | 0.00% | 94.19% | 0.00% |
| Operating Expenses | $34.83M | $44.45M | $41.90M | $40.39M | $33.44M | $27.89M | $39.99M | $35.81M |
| Operating Income | $-14.89M | $-12.99M | $-35.37M | $-35.07M | $-31.50M | $-28.88M | $-23.23M | $-37.41M |
| Operating Margin | -53.44% | -38.83% | -471.65% | -584.57% | -1574.80% | 0.00% | -130.49% | 0.00% |
| Net Income | $-14.23M | $-18.75M | $-33.69M | $-34.20M | $-29.70M | $-27.34M | $-22.60M | $-37.07M |
| Net Margin | -51.07% | -56.05% | -449.25% | -570.05% | -1484.90% | 0.00% | -126.96% | 0.00% |
| EPS (Basic) | $-0.16 | $-0.21 | $-0.39 | $-0.41 | $-0.37 | $-0.43 | $-0.41 | $-0.72 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |